Form 8-K - Current report

CONMED Corp false 0000816956 0000816956 2024-08-14 2024-08-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2024

 

 

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-39218		16-0977505
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11311 Concept Blvd

Largo, FL 33773

(Address of principal executive offices, including zip code)

[phone]

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		CNMD		NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

---

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)(2) On August 14, 2024, CONMED Corporation (the “Company”) announced that the employment of Stanley W. (Bill) Peters, the Company’s President, Advanced Surgical & Advanced Endoscopic Technologies, will terminate on August 31, 2024. In connection with his departure, Mr. Peters will receive the compensation and benefits payable on a non-change in control qualifying termination under the Company’s Executive Severance Plan, as described in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 8, 2024.

---

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

CONMED CORPORATION (Registrant)
By:		/s/ Curt R. Hartman
Name:		Curt R. Hartman
Title:		President and Chief Executive Officer

Date: August 14, 2024

Document and Entity Information	Aug. 14, 2024
Cover [Abstract]
Entity Registrant Name	CONMED Corp
Amendment Flag	false
Entity Central Index Key	0000816956
Document Type	8-K
Document Period End Date	Aug. 14, 2024
Entity Incorporation State Country Code	DE
Entity File Number	001-39218
Entity Tax Identification Number	16-0977505
Entity Address, Address Line One	11311 Concept Blvd
Entity Address, City or Town	Largo
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33773
City Area Code	(727)
Local Phone Number	392-6464
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.01 par value
Trading Symbol	CNMD
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

---